HC Wainwright & Co. Reiterates Buy on Mind Medicine, Maintains $35 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Mind Medicine (NASDAQ:MNMD) and maintained a $35 price target, as stated by analyst Patrick Trucchio.
May 24, 2024 | 4:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Mind Medicine (NASDAQ:MNMD) and maintained a $35 price target, indicating continued confidence in the company's growth prospects.
The reiteration of a Buy rating and the maintenance of a $35 price target by a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and could lead to a short-term increase in MNMD's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100